ERBB2 and breast carcinoma: Specifically, in HER2+ breast cancer, our findings are consistent with those of Gallagher et al., who reported that initiating adjuvant trastuzumab more than 6 months after breast cancer diagnosis was associated with significantly increased risks of relapse and mortality [13].